The Executive Report uses the expression 'best-in-class' to describe its proprietary drug delivery platform. I doubt whether there is a vote on this kind of thing. It would also be hollow if its entirely the thought bubble of Phylogica management. So the question arises as to who it is that considers the EET as best-in-class in delivering peptide-linked drugs inside cells?
There are a number of contenders and it would be logical to think that its from those who would have first hand knowledge of the validated data. Could it be the feedback which management is receiving at conferences and in phone calls from companies interested in collaborations?
"The Genentech agreement validates the industry's growing interest in Phylogica's biologics delivery technology."
So, who is it and what will it mean going forward!
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)